The effect of health insurance on childhood cancer survival has not been well studied. Using Surveillance, Epidemiology, and End Results (SEER) data, this study was designed to assess the association between health insurance status and childhood cancer survival. METHODS: Data on cancers diagnosed among children less than 15 years old from 2007 to 2009 were obtained from the SEER 18 registries. The effect of health insurance at diagnosis on 5-year childhood cancer mortality was estimated with marginal survival probabilities, restricted mean survival times, and Cox proportional hazards (PH) regression analyses, which were adjusted for age, sex, race/ethnicity, and county-level poverty. RESULTS: Among 8219 childhood cancer cases, the mean survival time was 1.32 months shorter (95% confidence interval [CI], 24.31 to 1.66) after 5 years for uninsured children (n 5 131) versus those with private insurance (n 5 4297), whereas the mean survival time was 0.62 months shorter (95% CI, 21.46 to 0.22) for children with Medicaid at diagnosis (n 5 2838). In Cox PH models, children who were uninsured had a 1.26-fold higher risk of cancer death (95% CI, 0.84-1.90) than those who were privately insured at diagnosis. The risk for those with Medicaid was similar to the risk for those with private insurance at diagnosis (hazard ratio, 1.06; 95% CI, 0.93-1.21). CONCLUSIONS: Overall, the results suggest that cancer survival is largely similar for children with Medicaid and those with private insurance at diagnosis. Slightly inferior survival was observed for those who were uninsured in comparison with those with private insurance at diagnosis. The latter result is based on a small number of uninsured children and should be interpreted cautiously. Further study is needed to confirm and clarify the reasons for these patterns.
INTRODUCTION
An estimated 10,380 US children younger than 15 years are diagnosed with cancer each year, with 1250 deaths projected for 2016. 1 Although the overall 5-year survival rate for patients with childhood cancer (age < 15 years) increased from 58% in the mid-1970s to 83% in 2005-2011, survival differences have been reported with respect to the cancer type and race/ethnicity. 2 For example, several studies have reported that Black children tend to have worse outcomes than White children, [3] [4] [5] [6] but few studies have considered the effects of socioeconomic factors on survival. In 2007, the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute began including patient-level insurance information as a standard data element. Several studies using data from the SEER 18 registries have reported that a lack of health insurance is associated with mortality for patients after a cancer diagnosis, including adolescents and young adults in the United States. [7] [8] [9] Nevertheless, the association between insurance status and childhood cancer survival has not been evaluated in a population-based study. Therefore, we aimed to assess whether insurance status is associated with childhood cancer mortality in a US population-based study.
MATERIALS AND METHODS

Study Population
We used data from 18 SEER registries 2 to identify all individuals who were diagnosed at an age less than 15 years with a first primary malignancy from 2007 to 2009. We restricted the study population to these years because the insurance status was first reported in 2007, and including cases diagnosed in 2007-2009 allowed for a full 5 years of follow-up. Raw data were extracted from the SEER*Stat program case listing session with age at diagnosis and year of diagnosis as parameters.
Variables
Our outcome of interest was death attributable to cancer, which was identified with the "SEER cause-specific death classification" variable. Our exposure of interest was insurance status at the time of diagnosis, which was identified with the "insurance recode (20071)" variable; this variable was coded as uninsured, any Medicaid, insured (private insurance, including military coverage), insured/ No specifics, or insurance status unknown. Private insurance, as defined by SEER, includes fee-for-service insurance, managed care, health maintenance organizations, preferred provider organizations, and TRICARE. 10 Childhood cancer subtypes were ascertained with the "ICCC site recode ICD-O-3/WHO 2008" variable, which is based on the International Classification of Childhood Cancer definition (third edition). 11 Age at diagnosis was based on the SEER variable "age recode with < 1 year olds." The race/ethnicity classification was based on the "race and origin recode (NHW, NHB, NHAIAN)" variable. Using this variable, we classified race/ethnicity as non-Hispanic White, non-Hispanic Black, Hispanic, or other. Individuals who self-identified as Hispanic were classified as Hispanic regardless of their race. Non-Hispanic American Indians/Alaska Natives, non-Hispanic Asians or Pacific Islanders, and nonHispanics of unknown race were classified as other. An individual-level measure for socioeconomic status was not available in the SEER database. As an alternative, we used the county-level poverty variable "% Families below poverty ACS 2009-13" 12 as a proxy for the percentage of families living below the poverty line in the county of residence at the time of the pediatric cancer diagnosis. We also used the "SEER historic stage A" variable, which classifies the extent of the disease as distant, localized, localized/regional (prostate cases), regional, or unstaged, to examine differences in stage distributions by insurance status and whether the stage was associated with the risk of cancer death. We did not use the American Joint Committee on Cancer stage variables because most cases were missing data for the American Joint Committee on Cancer stage. In addition, many pediatric cancer types were missing data or had unsuitable data for the SEER historic stage A variable (eg, all leukemia cases are classified as distant, and brain and other nervous system tumors are classified as unstaged).
13 Therefore, we excluded leukemias and cancer types with more than 20% missing data for the SEER historic stage A variable, and this left individuals diagnosed with retinoblastomas, renal tumors, hepatic tumors, bone tumors, soft-tissue sarcomas, and other malignant epithelial tumors for the analyses of stage.
Data Analyses
SAS version 9.4 and Stata version 14 were used for all statistical analyses. A survival time cutoff point of 60 months was used for analyses that included cases diagnosed from 2007 to 2009 to ensure that all subjects had the same window of observation. Person-time was calculated with the "survival months" variable, which was the time from the initial diagnosis of cancer to occurrence of death attributable to cancer or other causes or to the end of the observation period, whichever came first. For example, if a subject had been diagnosed in 2007 with a vital status that was recorded as alive as of December 31, 2012, the subject was censored at 60 months.
We estimated marginal (population-averaged) survival probabilities with a Cox proportional hazards (PH) framework, 14 and they were subsequently used to plot survival curves by insurance status. This approach allowed adjustments for multiple covariates, which would not be possible with standard Kaplan-Meier approaches. The resulting survival curves were interpreted as the average survival for childhood cancer patients, who were classified as having private insurance, having any Medicaid, having insurance (type unknown), or being uninsured at diagnosis, after accounting for covariates to reduce confounding bias. Specifically, we used a directed acyclic graph to encode dependency assumptions (ie, relations between variables) on the basis of prior knowledge for the relation between insurance status and childhood cancer mortality. On the basis of these dependencies, we applied the backdoor criterion (ie, paths between exposure and outcome that require blocking) to identify a minimal sufficient set of covariates to reduce confounding bias (Supporting Fig.  1 [see online supporting information]). 15, 16 Consequently, we adjusted for age at diagnosis, sex, race/ethnicity, and county-level poverty when we estimated marginal survival and for our main Cox PH regression analyses.
We also compared mean survival times by insurance status with a restricted mean survival time (RMST) analysis. [17] [18] [19] [20] [21] Unlike Cox PH models, for which valid estimates rely on the PH assumption, the RMST approach is valid for any distribution of the time to event. [17] [18] [19] [20] [21] In addition, estimates from the RMST approach have a more direct clinical interpretation because survival times, rather than hazards, are the parameter of interest. Briefly, the RMST requires designating time horizons (ie, endpoints of interest such as 60 months) for the comparisons of interest. We compared the absolute difference in the mean survival (with corresponding 95% confidence intervals [CIs]) by insurance status at a 60-month horizon with adjustments for age at diagnosis, sex, race/ethnicity, and county-level poverty with pseudovalues of the RMST and subsequent linear regression. 17, 20, 21 For example, an estimate of 22.0 in a comparison of uninsured and privately insured childhood cancer patients at 60 months would be interpreted as a 2-month shorter mean survival time for uninsured children versus privately insured children after 60 months of follow-up.
We used Cox PH regression to estimate hazard ratios (HRs) and 95% CIs for the association between insurance status at diagnosis (private insurance, insurance/No specifics, any Medicaid, or no insurance) and death attributable to cancer overall and by age group (0-4, 5-9, and 10-14 years); adjustments were made for age at diagnosis (except in the age group-stratified analyses), sex, race/ethnicity, and county-level poverty. Individuals with missing data for any variables included in the models were excluded. The survival time was recorded in months; for those with 0 months of survival time, 0.5 months was added to approximate the average survival time for those with <1-month survival because the SEER program records the survival time as a discrete value in months. The PH assumption was checked according to the methods described by Allison with Martingale residuals with the ASSESS PH/RESAMPLE statement in the SAS PHREG procedure. 22, 23 We also evaluated associations between insurance status at diagnosis and SEER historic stage A (regional/distant stage vs localized stage at diagnosis) with logistic regression and between SEER historic stage A and cancer mortality with Cox PH regression. We adjusted for the variables noted previously in both analyses and additionally for insurance status in the logistic regression analysis and the staged cancer type in the Cox PH regression analysis.
RESULTS
Of the 8432 cases diagnosed in 2007 to 2009 with a first primary cancer, 213 were missing data for covariates, and this left a total of 8219 individuals who were included in the analytic data set. For cancers overall, the age-atdiagnosis and sex distributions were similar across different insurance categories with the exception of those who were uninsured, for whom the highest percentage of cases was diagnosed at 10 to 14 years of age. The distribution of race varied by insurance category, with the majority of cases being White in the private insurance category (59.7%) and the minority being Black (8.4%). In contrast, the majority of cases were Hispanic among those with any Medicaid (48.1%) and those who were uninsured (45.0%). Among those who were privately insured at diagnosis, the majority of the cases were reported to be diagnosed in counties with lower levels of poverty, whereas among those who had any Medicaid or were uninsured at diagnosis, the opposite pattern was observed. There were no marked patterns in the distribution of cancer types by insurance status at diagnosis. Finally, among those who were privately insured at diagnosis, the highest percentage of staged cancer diagnoses occurred at localized stage (48.0%), with similar results for those with any Medicaid (47.4%). In contrast, for those who were uninsured at diagnosis, the lowest percentage of diagnoses occurred at localized stage (28.1%; Table 1 ). Figure 1 illustrates the 5-year marginal survival probabilities. The 5-year survival probability was lower for children who were uninsured, had any Medicaid, or were insured/No specifics in comparison with children who were privately insured at diagnosis. Only slight differences in survival were apparent between all groups.
In RMST analyses, in comparison with those who were privately insured at diagnosis, children who had any Medicaid at diagnosis and children who were uninsured at diagnosis had modestly lower survival at 60 months: 20.62 months less (95% CI, 21.46 to 0.22 months) and 21.32 months less (95% CI, 24.31 to 1.66 months), respectively ( Table 2) .
In Cox PH models, the risk of cancer death for children with any Medicaid and children who were uninsured at diagnosis was 6% higher (HR, 1.06; 95% CI, 0.93-1.21) and 26% higher (HR, 1.26; 95% CI, 0.84-1.90), respectively, in comparison with those who were privately insured at diagnosis. Among children with hematological malignancies, the risk of cancer death for those who were uninsured at diagnosis was 9% higher than the risk for those who were privately insured at diagnosis (HR, 1.09; 95% CI, 0.51-2.34), and the risk was slightly higher for those with any Medicaid (HR, 1.16; 95% CI, 0.92-1.47); however, these estimates were imprecise. The risk of central nervous system tumor death for children who had any Medicaid and children who were uninsured at diagnosis was 4% lower (HR, 0.96; 95% CI, 0.78-1.20) and 42% higher (HR, 1.42; 95% CI, 0.70-2.88), respectively, in comparison with children who were privately insured at diagnosis. In comparison with children who were privately insured at diagnosis, the risk of other childhood cancer death was increased by 15% for children who had any Medicaid (HR, 1.15; 95% CI, 0.92-1.44) and by 47% for those who were uninsured (HR, 1.47; 95% CI, 0.75-2.87; Table 3 ). Notably, all confidence intervals included the null value of 1, indicating that we cannot 
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To provide insights into possible reasons for the higher risk of cancer death in children who were reported as uninsured vs privately insured at diagnosis, we evaluated the association between insurance status and SEER historic stage A at diagnosis (regional/distant vs localized). A total of 1910 individuals with retinoblastomas, renal tumors, hepatic tumors, malignant bone tumors, softtissue and extraosseous sarcomas, and other malignant epithelial neoplasms and malignant melanomas were included in these analyses. In general, individuals who were uninsured at diagnosis were more likely to be diagnosed at a regional/distant stage for all cancer subtypes included in the analysis in comparison with privately insured individuals (Supporting Table 1 [see online supporting information]). Being uninsured at diagnosis increased the odds of a regional/distant stage diagnosis by 2.43-fold (95% CI, 1.09-5.42; Supporting Table 2 [see online supporting information]). We also examined whether SEER historic stage A was associated with an increased risk of cancer mortality and observed that individuals diagnosed at regional and distant stages compared to those diagnosed at localized stage were at higher risk for cancer death with HRs of 2.63 (95% CI, 1.84-3.76) and 8.48 (95% CI, 6.04-11.91), respectively (Supporting Table 3 [see online supporting information]). In addition, we examined the hazard of cancer death in association with insurance status for staged cancers. In comparison with those privately insured at diagnosis, the HRs were 1.23 (95% CI, 0.95-1.60) and 1.26 (95% CI, 0.95-1.65) for those with any Medicaid, 1.03 (95% CI, 0.70-1.50) and 1.20 (95% CI, 0.81-1.78) for those who were insured/No specifics, and 1.27 (95% CI, 0.56-2.87) and 1.06 (95% CI, 0.57-2.42) for the uninsured in models with and without stage at diagnosis included as a covariate, respectively (data not shown).
Finally, we evaluated the hazard of childhood cancer death in association with insurance status at diagnosis by age group (0-4, 5-9, and 10-14 years old at diagnosis). Among 0-to 4-year-olds, only those who were uninsured had an increased risk of cancer death in comparison with those who were privately insured at diagnosis (HR, 1.50; 95% CI, 0.82-2.75), and this was not statistically significant. Among 5-to 9-year-olds, the hazard of cancer death for those who had any Medicaid and those who were uninsured was increased 1.19-fold (95% CI, 0.93-1.53) and 1.25-fold (95% CI, 0.55-2.83), respectively, in comparison with those who were privately insured at diagnosis, and both confidence intervals included 1. Among 10-to 14-year-olds, the hazard of cancer death for those with any Medicaid was 1.38-fold higher (95% CI, 1.09-1.75) than the hazard for those who were privately insured at diagnosis (Supporting Table 4 [see online supporting information]).
DISCUSSION
Overall, our results suggest largely similar survival for privately insured children and those with Medicaid at diagnosis, with slight evidence for an increased hazard of cancer death for children who were uninsured versus those who were privately insured at diagnosis. However, the number of uninsured children was very small, and thus this latter result may be due to chance and should be interpreted with caution.
To our knowledge, the association between insurance status and childhood cancer mortality has not previously been evaluated in a population-based study. However, 2 studies based on SEER data have examined this association in adolescents and young adults. The first study used data from the SEER 18 registries and included young adults diagnosed with cancer at an age of 20 to 40 years from 2007 to 2009. After adjustments for age at diagnosis, median household income, sex, race, marital status, population density, cancer stage, and treatment received, the relative hazard of mortality from all causes for those who were insured versus those who were uninsured was 1.3 (95% CI, 1.10-1.54). 7 The second study also used data from the SEER 18 registries. This study included young adults diagnosed with cancer between the ages of 20 and 39 years from 2007 to 2010, and it reported that among non-privately insured patients with stage I/II cancer diagnoses, 20-to 24-year-olds and 24-to 39-year-olds had 2.6 and 2.9 times higher relative hazards Original Article of cancer-related mortality, respectively, than those with private health insurance after adjusting for age and race. 9 These studies had notable differences in insurance category definitions, covariate adjustment to reduce confounding bias, and exposure and outcome definitions. In particular, Aizer et al 7 combined patients with Medicaid and private insurance into an insured category, whereas Rosenberg et al 9 combined patients with Medicaid and no insurance at diagnosis into a non-private insurance category. Grouping Medicaid patients with either privately insured or uninsured patients creates challenges in interpreting the effects of insurance coverage on mortality in younger patients with cancer. Consequently, we did not combine categories for defining the insurance status.
A large percentage of US children (95%) have health insurance coverage through private health insurance, Medicaid, or the Children's Health Insurance Program (CHIP), 24, 25 but it was estimated in 2015 that close to 4 million US children (5%) still lacked health insurance. 26 Although based on relatively few uninsured children (n 5 131), we observed a higher relative hazard of childhood cancer mortality over 5 years of observation in this group versus the groups with private insurance or Medicaid. Notably, the relative hazard of cancer-related mortality was similar between children with any Medicaid and children with private insurance at diagnosis. This finding is consistent with prior reports suggesting that children on Medicaid or the state's CHIP have health care access comparable to that of children with private health insurance. 25, 26 Medicaid and CHIP provide a comprehensive set of benefits that include Early and Periodic Screening, Diagnostic and Treatment; checkups; and physician and hospital visits. 27, 28 Although one study reported worse health outcomes (eg, vision and dental health) in children with Medicaid versus those with private insurance, 29 our data provide evidence showing that Medicaid coverage results in outcomes for childhood cancer similar to the outcomes resulting from private insurance.
Our finding that survival is largely similar between children covered by Medicaid and those covered by private insurance is an important finding. A recent systematic review reported that a low socioeconomic status negatively affects childhood cancer outcomes in both low-and highincome countries. 30 Our results suggest that the type of insurance coverage (public vs private) does not affect the risk of death from cancer after adjustments for other factors. However, it is noteworthy that when we stratified the patients by age group, the mortality risk for those with any Medicaid versus those with private insurance at The percentages indicate those in each category who died of their cancer within the follow-up period.
diagnosis among 10-to 14-year-olds starts to look more like the pattern described previously for the adolescent and young adult population. We note, however, that these results are not directly comparable because of differences in insurance definitions. Nevertheless, the reasons for this pattern merit further investigation. Our finding that children who are uninsured at diagnosis are more likely to be diagnosed at a regional or distant stage than privately insured children and that these children in turn have a higher risk of cancer death than those with a localized stage at diagnosis is noteworthy. However, these results should be considered preliminary because we included only 5 cancer subtypes with sufficient staging information according to the SEER historic stage A categories 13 ; therefore, these results may apply only to individuals diagnosed with this group of childhood cancer subtypes. These data suggest a conceptual model: being uninsured may lead to diagnosis delays, which in turn leads to a higher stage at diagnosis (when cancer is generally more difficult to treat) and an increased risk of cancer death. It is unclear from the literature whether a lack of health insurance leads to diagnosis delays that result in worse cancer outcomes for children. In a review by DangTan and Franco 31 of diagnosis delays (defined by the authors as the time between symptoms and diagnosis) in childhood cancer, it is reported that "the main factors related to diagnosis delay were the child's age at diagnosis [older] , parent level of education, type of cancer, presentation of symptoms, tumor site, cancer stage, and the first medical specialty consulted." 31 However, none of the reviewed studies are reported to have examined whether health insurance status at diagnosis leads to diagnosis delays, and we could not find any published research specifically examining this association for US pediatric cancer cases. The association between diagnosis delays and pediatric cancer outcomes is an important area for future research.
Several limitations should be considered when interpreting our findings. In addition to the small number of uninsured individuals, which limited our conclusions, our estimates may be sensitive to misclassification of insurance status. Several studies have reported that uninsured patients at the time of their diagnosis tend to enroll in Medicaid, and retroactive Medicaid enrollment may occur more often among patients with more advanced-stage cancers. 9, 32, 33 In our study, insurance status was reported at diagnosis, and thus we could not account for changes in insurance status over the followup period in our study. The result would be misclassification of uninsured patients as Medicaid patients at baseline, which may have resulted in the observation of a lower survival rate among Medicaid patients. 32 In addition, any survival advantage for privately insured patients may be attributable to lead-time bias, which has been previously suggested as an explanation for survival disparities by insurance status among adults. 32 For example, if uninsured or Medicaid patients had later diagnoses than privately insured patients, this lead-time may give a false impression of longer survival among privately insured patients. Furthermore, as with any observational study of exposure-outcome associations, unmeasured confounding could be an alternative explanation for our findings. 34 Another limitation of the data is that poverty was measured at the county level and not at the individual level; we explored the specification of a multilevel model with poverty as a separate level. The estimates varied only up to 3% in comparison with poverty specified as an individual-level measure and did not affect the interpretation, and thus we chose to report estimates based on the simpler (nonmultilevel) model. Nevertheless, a county-level measure cannot fully substitute for an individual-level measure of socioeconomic status for the controlling of confounding by poverty. Residual confounding is thus a possibility, but we would anticipate negative confounding (given an inverse association between poverty and insurance status and a positive association between poverty and childhood cancer mortality) in this scenario. The consequences would be potentially underestimated effects of insurance status on childhood cancer mortality.
In summary, children with Medicaid had largely similar survival in comparison with children with private insurance at diagnosis, with a possibly increased hazard of cancer death for 10-to 14-year-olds with Medicaid at diagnosis. We observed slight evidence for an increased hazard of cancer death for uninsured children that may be related to a more advanced cancer at diagnosis. However, the small number of uninsured children contributes to uncertainty in our results. Therefore, these results should be interpreted cautiously and will need to be confirmed in a larger study before firm conclusions can be reached. Our results pertain to the first 5 years after a childhood cancer diagnosis. Longer follow-up in future studies may provide additional insights into whether the patterns observed in our study are sustained. If our results are valid, then national or state health care policies that provide at least coverage with Medicaid for otherwise uninsured children may improve overall survival for children diagnosed with cancer.
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